← Back to Search

Bile Acid

Ursodeoxycholic Acid for Sarcoidosis

Phase 2
Waitlist Available
Research Sponsored by Ethan Weinberg
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 6 months after initiation of udca
Awards & highlights

Study Summary

This study is evaluating whether a drug may help improve liver function and quality of life for individuals with liver disease.

Eligible Conditions
  • Sarcoidosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 6 months after initiation of udca
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 6 months after initiation of udca for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Alkaline Phosphatase (U/L) or Gamma Glutamyl Transferase (U/L) 6 Months After Initiation of Ursodeoxycholic Acid
Secondary outcome measures
ALT
AST
Bilirubin
+1 more

Side effects data

From 2015 Phase 2 trial • 66 Patients • NCT01904058
100%
Abdominal Pain
100%
Diarrhoea
100%
Dizziness
100%
Nausea
100%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
LUM001 5 mg + UDCA
LUM001 10 mg + UDCA
LUM001 20 mg + UDCA
Placebo + UDCA

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: UDCA at Month 6Experimental Treatment1 Intervention
Group II: ObservationActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ursodeoxycholic acid
FDA approved

Find a Location

Who is running the clinical trial?

Meridian Bioscience, Inc.Industry Sponsor
32 Previous Clinical Trials
12,742 Total Patients Enrolled
Ethan WeinbergLead Sponsor
American Association for the Study of Liver DiseasesOTHER
5 Previous Clinical Trials
202 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
Ethan Weinberg 2018. "Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03602976.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top